Latest News

Image-guided superficial radiation as first-line in skin cancer?


 

The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed.

Key takeaway

  • Absolute lesion control rate with image-guided superficial radiation therapy (IGSRT) for early-stage nonmelanoma skin cancer was achieved in nearly all patients.

Why this matters

  • IGSRT is a newer radiation technique for skin cancer, an alternative to Mohs micrographic surgery and other surgical options.
  • The ultrasound imaging used during IGSRT allows for precise targeting of cancer cells while sparing surrounding tissue.
  • IGSRT is currently recommended for early-stage nonmelanoma skin cancer among patients who refuse or cannot tolerate surgery.
  • Given the safety, lack of surgical disfigurement, cost-effectiveness, and high cure rate, IGSRT should be considered more broadly as a first-line option for early-stage nonmelanoma skin cancer, the researchers concluded.

Study design

  • The investigators reviewed 1,899 early-stage nonmelanoma skin cancer lesions in 1,243 patients treated with IGSRT at an outpatient dermatology clinic in Dallas.
  • Energies ranged from 50 to 100 kV, with a mean treatment dose of 5,364.4 cGy over an average of 20.2 fractions.
  • Treatment duration was a mean of 7.5 weeks and followed for a mean of 65.5 weeks.

Key results

  • Absolute lesion control was achieved in 99.7% of patients, with a stable control rate of 99.6% past 12 months.
  • At a 5-year follow-up, local control was 99.4%.
  • Local control for both basal and squamous cell carcinoma at 5 years was 99%; local control for squamous cell carcinoma in situ was 100% at 5 years.
  • The most common side effects were erythema, dryness, and dry desquamation. Some patients had ulceration and moist desquamation, but it did not affect lesion control.
  • The procedure was well tolerated, with a grade 1 Radiation Treatment Oncology Group toxicity score in 72% of lesions.
  • The results compare favorably with Mohs surgery.

Limitations

  • No study limitations were noted.

Disclosures

  • No funding source was reported.
  • Senior investigator Lio Yu, MD, reported research, speaking and/or consulting for SkinCure Oncology, a developer of IGSRT technology.

This is a summary of a preprint research study, “Analysis of Image-Guided Superficial Radiation Therapy (IGSRT) on the Treatment of Early Stage Non-Melanoma Skin Cancer (NMSC) in the Outpatient Dermatology Setting,” led by Alison Tran, MD, of Baylor University Medical Center, Dallas. The study has not been peer reviewed. The full text can be found at medRxiv.org.

A version of this article first appeared on Medscape.com.

Recommended Reading

Pick your sunscreen carefully: 75% don’t pass muster
Federal Practitioner
Bupivacaine following Mohs surgery reduces opioid use, study finds
Federal Practitioner
Mohs surgery in the elderly: The dilemma of when to treat
Federal Practitioner
Surgical site infections not increased in immunocompromised patients after Mohs surgery
Federal Practitioner
Quality of life benefit exaggerated in some cancer studies
Federal Practitioner
FDA acts against sales of unapproved mole and skin tag products on Amazon, other sites
Federal Practitioner
Experts: EPA should assess risk of sunscreens’ UV filters
Federal Practitioner
Consider the ‘long game’ in tumor management following Mohs surgery
Federal Practitioner
FDA warns of cancer risk in scar tissue around breast implants
Federal Practitioner
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Federal Practitioner